Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirk R Henne

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Current Opinion in Drug Discovery & Development|February 1, 2006
The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolismMichael B Fisher, Kirk R Henne, Jason Boer
Chemical Research in Toxicology|May 17, 2005
Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediateBrian R Baer, Allan E Rettie, Kirk R Henne
Biochemical and Biophysical Research Communications|December 13, 2006
A comparison of substrate dynamics in human CYP2E1 and CYP2A6John P Harrelson, Kirk R Henne, Darwin O V Alonso, et al.
Biochemistry|April 16, 2003
Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediateYi-Min Zheng, Brian R Baer, M Byron Kneller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 27, 2010
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interactionSimon G Wong, Peter W Fan, Raju Subramanian, et al.
Toxicology and Applied Pharmacology|March 18, 2003
Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysisYi-Min Zheng, Kirk R Henne, Patrick Charmley, et al.
Chemico-Biological Interactions|June 28, 2005
Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4Amit S Kalgutkar, Kirk R Henne, Mary E Lame, et al.
Biopharmaceutics & Drug Disposition|September 1, 2006
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomesAmit S Kalgutkar, Heather L Hatch, Frederick Kosea, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 4, 2004
Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4Amit S Kalgutkar, Alfin D N Vaz, Mary E Lame, et al.
Current Drug Metabolism|June 25, 2005
A comprehensive listing of bioactivation pathways of organic functional groupsAmit S Kalgutkar, Iain Gardner, R Scott Obach, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Current Opinion in Drug Discovery & Development|February 1, 2006
The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolismMichael B Fisher, Kirk R Henne, Jason Boer
Chemical Research in Toxicology|May 17, 2005
Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediateBrian R Baer, Allan E Rettie, Kirk R Henne
Biochemical and Biophysical Research Communications|December 13, 2006
A comparison of substrate dynamics in human CYP2E1 and CYP2A6John P Harrelson, Kirk R Henne, Darwin O V Alonso, et al.
Biochemistry|April 16, 2003
Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediateYi-Min Zheng, Brian R Baer, M Byron Kneller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 27, 2010
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interactionSimon G Wong, Peter W Fan, Raju Subramanian, et al.
Toxicology and Applied Pharmacology|March 18, 2003
Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysisYi-Min Zheng, Kirk R Henne, Patrick Charmley, et al.
Chemico-Biological Interactions|June 28, 2005
Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4Amit S Kalgutkar, Kirk R Henne, Mary E Lame, et al.
Biopharmaceutics & Drug Disposition|September 1, 2006
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomesAmit S Kalgutkar, Heather L Hatch, Frederick Kosea, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 4, 2004
Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4Amit S Kalgutkar, Alfin D N Vaz, Mary E Lame, et al.
Current Drug Metabolism|June 25, 2005
A comprehensive listing of bioactivation pathways of organic functional groupsAmit S Kalgutkar, Iain Gardner, R Scott Obach, et al.
Pageof 2